Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab for AMR Prevention in Positive Crossmatch Kidney Transplant
NCT00670774Phase 2Completed
- Start
- Mar 2008
- Primary completion
- May 2017
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of eculizumab in antibody mediated rejection (AMR). Started Mar 2008; status: completed.
02
Drugs
eculizumab
03
Conditions
antibody mediated rejection (AMR)
Beyond the preview
Go deeper on NCT00670774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00670774.